Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer

Frontiers in Oncology

Volumn 3 APR, Issue , 2013, Pages

  Konkalmatt, Prasad R ^a   Deng, Defeng ^b   Thomas, Stephanie ^a   Wu, Michael T ^a   Logsdon, Craig D ^b   French, Brent A ^a,c,d   Kelly, Kimberly A ^a,c  

^a University of Virginia   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

AAV; Capsid modification; Gene therapy; Pancreatic cancer; Phage display; Targeted gene delivery

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; LUCIFERASE; PARVOVIRUS VECTOR; PLECTIN;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; CONTROLLED STUDY; GENE TARGETING; GENE THERAPY; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; MOLECULAR IMAGING; MOUSE; NONHUMAN; PANCREAS CANCER; PLASMID; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE ALIGNMENT; TUMOR XENOGRAFT;

EID: 84879792979     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00084     Document Type: Article

References (23)

1. Bausch, D., Thomas, S., Mino-Kenudson, M., Fernández-Del, C. C., Bauer, T. W., Williams, M., et al. (2011). Plectin-1 as a novel biomarker for pancreatic cancer. Clin. Cancer Res. 17, 302-309.
2. Geer, R., and Brennan, M. (1993). Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am. J. Surg. 165, 68-72.
3. Girod, A., Ried, M., Wobus, C., Lahm, H., Leike, K., Kleinschmidt, J., et al. (1999). Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nat. Med. 5, 1052-1056.
4. Grifman, M., Trepel, M., Speece, P., Gilbert, L. B., Arap, W., Pasqualini, R., et al. (2001). Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids. Mol. Ther. 3, 964-975.
5. Hernandez, Y. J., Wang, J., Kearns, W. G., Loiler, S., Poirier, A., and Flotte, T. R. (1999). Latent adeno-associated virus infection elicits humoral but not cell-mediated immune responses in a nonhuman primate model. J. Virol. 73, 8549-8558.
6. Hezel, A., Kimmelman, A., Stanger, B., Bardeesy, N., and Depinho, R. (2006). Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 20, 1218-1249.
7. Hwang, R. F., Moore, T., Arumugam, T., Ramachandran, V., Amos, K. D., Rivera, A., et al. (2008). Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res. 68, 918-926.
8. Kelly, K., Bardeesy, N., Anbazhagan, R., Gurumurthy, S., Berger, J., Alencar, H., et al. (2008). Targeted nanoparticles for imaging incipient pancreatic ductal adenocarcinoma. PLoS Med. 5:e85. doi:10.1371/journal.pmed.0050085
9. Kern, A., Schmidt, K., Leder, C., Muller, O. J., Wobus, C. E., Bettinger, K., et al. (2003). Identification of a heparin-binding motif on adeno-associated virus type 2 capsids. J. Virol. 77, 11072-11081.
10. Liu, N., Furukawa, T., Kobari, M., and Tsao, M.-S. (1998). Comparative phenotypic studies of duct epithelial cell lines derived from normal human pancreas and pancreatic carcinoma. Am. J. Pathol. 153, 263-269.
11. Nicklin, S. A., Buening, H., Dishart, K. L., De Alwis, M., Girod, A., Hacker, U., et al. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174-181.
12. Nicklin, S. A., Dishart, K. L., Buening, H., Reynolds, P. N., Hallek, M., Nemerow, G. R., et al. (2003). Transductional and transcriptional targeting of cancer cells using genetically engineered viral vectors. Cancer Lett. 201, 165-173.
13. Prasad, K.-M. R., Xu, Y., Yang, Z., Acton, S. T., and French, B. A. (2011). Robust cardiomyocyte-specific gene expression following systemic injection of AAV: in vivo gene delivery follows a Poisson distribution. Gene Ther. 18, 43-52.
14. Prasad, K.-M. R., Xu, Y., Yang, Z., Toufektsian, M.-C., Berr, S. S., and French, B. A. (2007). Topoisomerase inhibition accelerates gene expression after adeno-associated virus-mediated gene transfer to the mammalian heart. Mol. Ther. 15, 764-771.
15. Qing, K., Mah, C., Hansen, J., Zhou, S., Dwarki, V., and Srivastava, A. (1999). Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat. Med. 5, 71-77.
16. Reynolds, P. N., Nicklin, S. A., Kaliberova, L., Boatman, B. G., Grizzle, W. E., Balyasnikova, I. V., et al. (2001). Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo. Nat. Biotechnol. 19, 838-842.
17. Summerford, C., Bartlett, J. S., and Samulski, R. J. (1999). AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat. Med. 5, 78-82.
18. Summerford, C., and Samulski, R. J. (1998). Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J. Virol. 72, 1438-1445.
19. Walters, R. W., Agbandje-McKenna, M., Bowman, V. D., Moninger, T. O., Olson, N. H., Seiler, M., et al. (2004). Structure of adeno-associated virus serotype 5. J. Virol. 78, 3361-3371.
20. Work, L. M., Büning, H., Hunt, E., Nicklin, S. A., Denby, L., Britton, N., et al. (2006). Vascular bed-targeted in vivo gene delivery using tropism-modified adeno-associated viruses. Mol. Ther. 13, 683-693.
21. Work, L. M., Nicklin, S. A., Brain, N. J. R., Dishart, K. L., Von Seggern, D. J., Hallek, M., et al. (2004). Development of efficient viral vectors selective for vascular smooth muscle cells. Mol. Ther. 9, 198-208.
22. Wu, J. C., Inubushi, M., Sundaresan, G., Schelbert, H. R., and Gambhir, S. S. (2002). Optical imaging of cardiac reporter gene expression in living rats. Circulation 105, 1631-1634.
23. Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., et al. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635-8647.